Andrew Cheng, MD, PhD
Former President and CEO
Akero Therapeutics
Andrew Cheng led Akero Therapeutics as president and chief executive officer from 2018 through its 2025 acquisition by Novo Nordisk for $5.2 billion. Akero focused on the development of efruxifermin, an FGF-21 analog, for the treatment of MASH. Previously, he spent nearly two decades at Gilead Sciences, where his last role was chief medical officer. During his tenure, he was responsible for the clinical development of the HIV program resulting in 11 FDA approved products, including Biktarvy, currently the leading product for HIV therapy. Andrew serves on the board of directors of Vera Therapeutics (VERA) and is board chairman for privately held Expedition Therapeutics. Dr. Cheng received his M.D. and Ph.D. from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.
Sessions
-
24-Jun-202628ABCDEFireside Chat: Novo Nordisk + Akero: Behind the Scenes of a Landmark Deal
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}